Even though lung and related cancer deaths decreased in the world's 10 most populous countries from 1990 to 2019, these ...
For patients with advanced or recurrent endometrial cancer, first-line Lenvima plus Keytruda didn’t significantly improve ...
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the ...
TrialTranslator uses machine learning to assess cancer RCT generalizability, revealing survival gaps for high-risk patients ...
Boehringer Ingelheim announced a partnership with Synaffix to advance antibody-drug conjugates and exercised its fourth ...
Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 ...
MarketBeat on MSN2h
Zymeworks in Focus for Insider Activity: Catalysts AheadZymeworks (NYSE: ZYME) came into focus in late December when major shareholder EcoR1 Capital increased its stake. Already a ...
IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after deciding to halt further development of a program relating to its autoimmunity-drug pipeline, sending its stock down 69% in ...
Top stocks for 2025 are from the companies that have proven growth track records and strong outlooks, with more potential ...
A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...
Chicago-based Meitheal Pharmaceuticals, along with its Chinese parent, was busy in 2024, adding both biosimilar drugs and ...
Women diagnosed with advanced breast cancer appeared more likely than those with earlier-stage breast cancer to have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback